Factors Associated With External and Internal Lymphedema in Patients With Head-and-Neck Cancer

2012 ◽  
Vol 84 (3) ◽  
pp. e319-e328 ◽  
Author(s):  
Jie Deng ◽  
Sheila H. Ridner ◽  
Mary S. Dietrich ◽  
Nancy Wells ◽  
Kenneth A. Wallston ◽  
...  
2019 ◽  
Vol 129 (11) ◽  
pp. 2491-2495 ◽  
Author(s):  
Dun‐Cheng Chang ◽  
Andy Wei‐Ge Chen ◽  
Yu‐Sheng Lo ◽  
Yi‐Ching Chuang ◽  
Mu‐Kuan Chen

Head & Neck ◽  
2020 ◽  
Vol 42 (9) ◽  
pp. 2696-2721 ◽  
Author(s):  
Sarah J. Geer ◽  
Phillip V. Rijn ◽  
Jan L.N. Roodenburg ◽  
Pieter U. Dijkstra

2019 ◽  
Vol 28 (6) ◽  
pp. 1159-1183 ◽  
Author(s):  
Laura H.A. Korsten ◽  
Femke Jansen ◽  
Ben J.F. Haan ◽  
Danielle Sent ◽  
Pim Cuijpers ◽  
...  

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
I. Zapata ◽  
M. Alvarez ◽  
R. Hidalgo ◽  
B. Pajares ◽  
M. J. Garcia-Anaya ◽  
...  

Abstract Background To investigate the incidence of non-cancer mortalities and prognostic factors associated with competitive causes of death in a homogeneous cohort of patients with locally advanced head and neck cancer treated with radiotherapy and systemic treatment. Methods This study included 284 patients with locally advanced head and neck cancer treated with radiotherapy and systemic treatment between 2005 and 2017. The cumulative incidence of death associated with tumour, second tumours, treatment, side effects and comorbidity was calculated. A Fine and Gray regression model was used to investigate factors associated with cancer and competitive mortality. Results The cumulative incidence of tumoral death at 5 and 10 years were 35 and 47% respectively, whereas the cumulative incidence of competitive mortality were 10 and 12% respectively. In the multivariate analysis, age and comorbidity were independent factors for non-cancer mortality. Patients with a high risk of non-cancer mortality presented a cumulative incidence of 17.3% at 5 years and 18.4% at 10 years. Conclusions This study demonstrated a high incidence of competing mortality in older patients with comorbidities. Non-cancer deaths should be considered when selecting patients for combination therapies and in the study design ofclinical trials.


2006 ◽  
Vol 132 (8) ◽  
pp. 874
Author(s):  
M. Schultzel ◽  
G. Robins-Sadler ◽  
K. L. Clark ◽  
M. Loscalzo ◽  
R. Weisman ◽  
...  

2014 ◽  
Vol 134 (10) ◽  
pp. 1079-1085 ◽  
Author(s):  
Yukinori Takenaka ◽  
Masashi Yamamoto ◽  
Susumu Nakahara ◽  
Yoshifumi Yamamoto ◽  
Toshimichi Yasui ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document